Akt signalling has emerged as one of the major pathways involved in myelination, implicated in the regulation of several steps during the development of myelinating Schwann cells and oligodendrocytes. One of the main pathways intimately linked with Akt is mTOR [mammalian (or mechanistic) target of rapamycin] signalling. Recent evidence suggests that many processes attributed to the Akt pathway in myelination depend, at least partly, on mTOR signalling. In the present mini-review, we summarize the major aspects of Akt/mTOR signalling and myelination, and how they appear to be linked. We focus on the PNS (peripheral nervous system), but also cover the key points of CNS (central nervous system) myelination, pointing out differences and similarities between the PNS and the CNS.
One of the major pathways intimately linked with Akt signalling is the mTOR pathway ( Figure 1 ). mTOR is the core kinase in two structurally and functionally distinct complexes, mTORC1 and mTORC2, which, in addition to several other proteins, contain the highly conserved adaptor proteins raptor (regulatory associated protein of mTOR) and rictor (rapamycin-insensitive companion of mTOR) respectively [6] . mTORC1 is a signalling hub integrating the major signals necessary for cell growth and proliferation, such as growth factors, nutrients, energy and oxygen ( Figure 1 ). mTORC2, which is mainly under growth factor control, has traditionally been viewed to have a relatively smaller role in mTOR signalling, but this concept is rapidly evolving. In general, mTOR signalling plays a particularly prominent role in metabolic organs to regulate whole body homoeostasis, with an important function also in aging [7] . Much of the knowledge on mTOR signalling has come from studies using the drug rapamycin, which inhibits many (but not all) of the activities of mTORC1 [8] . mTORC2, on the other hand, is insensitive to short-term rapamycin treatment, whereas prolonged treatment also inhibits mTORC2, probably due to blocking of the assembly of new mTORC2 [9] .
The links between Akt and mTOR signalling are manifold ( Figure 1 ). Upon growth factor stimulation, Akt phosphorylates the GAP (GTPase-activating protein) TSC2 (tuberous sclerosis complex 2) in the TSC-TBC (Tre-2/Bub2/Cdc16) complex, thereby inhibiting its GAP activity towards Rheb, a Ras family GTPase [10] . GTP-bound active Rheb in turn stimulates the kinase activity of mTORC1. However, Akt can also activate mTORC1 independently of the TSC-TBC complex [6] . Moreover, TSC2 activity, and thus mTORC1 activity, can also be regulated by many proteins other than Akt. In parallel to the PI3K-Akt axis, growth factors also stimulate the MAPK (mitogenactivated protein kinase)-ERK (extracellular-signal-regulated kinase) 1/2 pathway [11] . The precise role and importance of this alternative axis from growth factors to mTORC1 remains to be elucidated, but will probably vary between Figure 1 Main players of the Akt/mTOR signalling pathway mTORC1 integrates signals from amino acids, oxygen levels, energy status and growth factors to regulate numerous cellular functions involved in cell growth and proliferation. These include lipid synthesis, adipogenesis, mitochondrial and glycolytic metabolism, autophagy and protein synthesis. Many of the upstream signals affecting mTORC1 act via the TSC-TBC complex, which negatively regulates mTORC1 activity by acting as a GAP for the Rheb GTPase, which in turn stimulates mTORC1 activity when GTP-bound. Low energy status and oxygen levels can inhibit mTORC1 signalling, for example via AMPK (AMP-activated protein kinase), which can inhibit mTORC1 either directly or indirectly by activating the TSC-TBC complex. Amino acids activate mTORC1 via Rag GTPases and the ragulator on the lysosomal surface. Growth factor stimulation leads to phosphorylation of Akt, which can activate mTORC1 both directly or via the TSC-TBC complex. Growth factors can also activate mTORC1 through the MAPK pathway. In addition to mTORC1, Akt regulates also cell survival and metabolism. For full activity, Akt requires phosphorylation by mTORC2 on Ser 473 in addition to the Thr 308 phosphorylation by PDK1. PtdIns(3,4,5)P 3 (PIP3) levels, and thereby PDK1 activity, is counteracted by PTEN. In contrast with mTORC1, mTORC2 is mainly regulated by growth factors, and, in addition to Akt, it also regulates for example SGK1, PKCα and cytoskeletal organization. Negative-feedback loops from S6K1 to IRS1 and rictor/mTORC2 add further complexity to the pathway. Atg13, autophagy 13; Deptor, DEP domain-containing mTOR-interacting protein; FOXO, forkhead box O; Ins, insulin; mLST8, mammalian lethal with sec-13 protein 8; mSIN1, mammalian stress-activated protein kinase-interaction protein 1; PRAS40, proline-rich Akt substrate of 40 kDa; Protor1, protein observed with rictor 1; REDD1, regulated in development and DNA damage responses 1; TBC1D7, TBC1 domain family, member 7; ULK1, unc51-like kinase 1.
different tissues. For a more comprehensive review on mTOR signalling, we refer the readers to previously published reviews, such as Laplante and Sabatini [6] .
Downstream of Akt/mTOR
Akt belongs to the family of AGC kinases, and phosphorylates a large number of substrates involved in cell growth, survival, metabolism and proliferation, among others, with many of the targets likely to be involved in several of these cellular functions (reviewed in [1] ). As discussed above, the main targets of Akt involved in cell growth are TSC2 and mTORC1. Targets implicated in cell survival are BAD (Bcl-2-associated death promoter) and FOXO (forkhead box O), whereas targets involved in metabolism include GSK3 (glycogen synthase kinase 3) and PGC-1α [PPARγ (peroxisome-proliferator-activated receptor γ ) coactivator 1α]. mTORC1 has, to date, a more limited repertoire of direct substrates than does Akt. The most classic and much studied direct downstream targets of mTORC1 are S6K1 (ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1), both of which are parts of the protein translation machinery. Apart from S6K1 and 4E-BP1, mTORC1 also up-regulates the protein synthesis machinery in other ways, for example by transcriptional regulation and RNA processing [6] . In addition to protein production, other processes involved in cell growth and biosynthesis are also regulated by mTOR signalling. On the catabolic side, mTORC1 inhibits autophagy by phosphorylating ULK1 (unc51-like kinase 1) and Atg13 (autophagy 13) among others, whereas on the anabolic side, mTOR signalling promotes mitochondrial and glycolytic metabolism, as well as lipid synthesis and metabolism [6] . Many of the metabolic processes that mTORC1 controls are regulated on the transcriptional level: HIF1α (hypoxia-inducible factor 1α) controls genes involved in glycolytic metabolism [12] , YY1 (yin-yang 1) and PGC-1α regulate mitochondrial oxidative function [13] , whereas lipid synthesis and adipogenesis are under the control of PPARγ and SREBP (sterol-regulatoryelement-binding protein) [12, 14, 15] . mTORC2 regulates cytoskeletal organization and cell survival and metabolism through phosphorylation and activation of many AGC kinases, including Akt, SGK1 (serum-and glucocorticoid-induced protein kinase 1) and PKCα (protein kinase Cα). Perhaps the most prominent role of mTORC2 is to phosphorylate Akt on Ser 473 in its hydrophobic motif, which is required for maximal activity of Akt [5] .
An additional link in the complex Akt/mTOR pathway is the feedback loops connecting Akt to downstream events of mTORC1 signalling. Constantly activated mTORC1 signalling modulates Akt via negative-feedback loops that act to suppress PI3K and subsequent Akt activity, thus partly uncoupling Akt from RTKs and insulin signalling. Consequently, these processes contribute to insulin resistance, which in turn can lead to Type 2 diabetes. The most studied negative-feedback loop involves S6K1 phosphorylating the insulin signalling adaptor protein IRS1, thereby decreasing its stability and thus diminishing the positive effect of IRS1 on recruiting and activating PI3K [16] . Other negative-feedback mechanisms also exist, of which at least the Grb10 (growthfactor receptor-bound protein 10)-mediated mechanism acts simultaneously with the IRS1-mediated feedback loop [17, 18] . Suppression of PDGFR (platelet-derived growth factor receptor) expression has also been suggested to act as a negative-feedback mechanism from mTORC1 [19] . Furthermore, activated S6K1 directly phosphorylates rictor, leading to partial inhibition of mTORC2 activity on phosphorylating Akt on Ser 473 , revealing cross-talk between mTORC1 and mTORC2 as well as an additional feedback loop [20] .
Interestingly, insulin and Akt can stimulate glucose and lipid metabolism also independently of mTORC1, at least in the liver [21] [22] [23] . mTORC2 is necessary for GK (glucokinase) and SREBP1c activation in the liver in parallel to mTORC1 [21, 23] , whereas hepatic SREBP1c can also be activated through an Akt-mediated suppression of the SREBP inhibitor Insig2a [22] .
Myelination
Myelination of axons is required for rapid saltatory conduction of nerve signals along the axon and thus for correct functioning of the nervous system. The overall conduction velocity of the myelinated axon is foremost determined by the myelin thickness, but also by its integrity, internodal length and nodal composition [24] . Myelin is produced by glial cells, oligodendrocytes in the CNS (central nervous system) and Schwann cells in the PNS (peripheral nervous system). During myelination, the glial cells extend their specialized plasma membranes spirally around axons, producing a compact multilayered myelin sheath, where the thickness of the complete myelin layer is proportional to the axon diameter. Defective myelination, due to either genetic or acquired factors, can lead to neurological diseases including multiple sclerosis, leukodystrophies and peripheral neuropathies, such as different forms of Charcot-MarieTooth disease [24] .
Signalling in myelination
During PNS development, the final differentiation step, i.e. myelination, takes place largely postnatally. Before that, Schwann cell precursors develop into immature Schwann cells, which further proliferate and differentiate into promyelinating Schwann cells. These cells, which now are engaging individual axons in a 1:1 relationship, start to wrap their plasma membrane around the axons in the process of myelination. Although the development of Schwann cells requires a multitude of signals, nearly all steps, including proliferation, differentiation and control of myelin sheath thickness, are controlled by one key regulator, the growth factor NRG1 (neuregulin-1) (reviewed in [25] ). NRG1 type III, the major isoform responsible for Schwann cell development, is exposed on the axonal membrane and binds to heterodimeric ErbB2/ErbB3 tyrosine kinase receptors on the Schwann cell surface, leading to subsequent activation of several second messenger cascades, including Ca 2 + , MAPK and PI3K pathways (reviewed in [26] ). In many settings, the PI3K rather than the MAPK pathway seems to be the preferential pathway downstream of NRG1-III signalling, at least for Schwann cell proliferation, survival, differentiation and early myelination [25] . However, ERK/MAPK signalling is also essential for multiple stages of Schwann cell development and regulates many aspects of PNS myelination [27] . In contrast with the PNS, the importance of NRG1 in the CNS remains somewhat controversial [28] .
Activation of PI3K by NRG1/ErbB signalling leads to conversion of PtdIns(4,5)P 2 into PtdIns(3,4,5)P 3 by PDK1, which in turn leads to phosphorylation of Akt on Thr 308 (discussed above). The formation of PtdIns(3,4,5)P 3 in nerves is tightly regulated, and the promoting PI3K activity is antagonized by the lipid phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10). Conditional knockout of PTEN in oligodendrocytes and Schwann cells in mice led to increased PtdIns(3,4,5)P 3 levels and consequently increased Akt phosphorylation, accompanied by increased phosphorylation of the mTORC1 secondary target S6, at least in sciatic nerves [29, 30] . Importantly, these Pten-mutant mice also displayed greatly increased myelin thickness in both the CNS and the PNS [29] . More specifically, PTEN deficiency caused hypermyelination mainly of the smallcalibre axons in the PNS, whereas larger axons rather showed focal hypermyelination, such as outfoldings and tomacula [29, 30] . When subjected to rapamycin treatment, mice lacking PTEN showed an impeded increase of white matter volume and an improvement in the PNS myelin abnormalities, confirming that the mTOR pathway lies downstream of PtdIns(3,4,5)P 3 signalling. In agreement with the Ptenknockout-associated hypermyelination, also silencing Dlg1, an essential interaction partner of PTEN, led to increased Akt phosphorylation and subsequent hypermyelination in sciatic nerves [31] . Conversely, silencing Akt2 in Schwann cells resulted in decreased myelin sheath thickness [31] . Furthermore, transgenic mice overexpressing a constitutively active form of Akt (Akt-DD) in oligodendrocytes and Schwann cells showed enhanced myelination and myelin protein expression, as well as increased mTORC1 activity [32] . Interestingly, however, hypermyelination was only observed in the CNS and not in the PNS. Similarly to Ptenmutant mice, administration of rapamycin to Akt-DD mice prevented CNS hypermyelination, indicating that, at least in the CNS, the mTOR pathway is the major effector pathway of the Akt-induced myelination [33] . Correspondingly, rapamycin treatment in wild-type mice led to a reduction in CNS myelin [33] . Also, myelin protein expression in the brain was reduced upon rapamycin treatment, both in wild-type and Akt-DD mice [32, 33] . In vitro studies in oligodendrocytes similarly revealed reduced expression of myelin proteins, increased expression of transcriptional repressors of differentiation, and reduced differentiation after treatment with rapamycin [34] . Interestingly, using siRNAs (short interfering RNAs) instead of rapamycin, it was shown that raptor and rictor have differential effects on myelin protein expression, with only rictor affecting the mRNA levels, whereas raptor affects the expression via alternative mechanisms [34] . In another study, Akt-DD transgenic mice were crossed with mice lacking BACE1 (β-site amyloid precursor protein-cleaving enzyme 1), an endopeptidase that cleaves NRG1-III [35] . Bace1-null mice exhibit hypomyelination in both the CNS and the PNS, probably due to insufficient Nrg1/PI3K/Akt signalling. Consistent with the previous study using Akt-DD mice, the constitutively active Akt in the Bace1 − / − /Akt-DD mice was sufficient to rescue hypomyelination only in the CNS, but not in the PNS [35] . Moreover, knockout of Rheb1 in neural progenitors (which give rise to glial cells in the CNS) led to postnatal hypomyelination due to defective differentiation of oligodendrocytes [36] . These mice also showed impaired mTORC1 signalling, suggesting that the defects were indeed due to a deficient mTOR cascade. Conversely, transgenic mice expressing a GAPresistant form of Rheb1 displayed increased mTORC1 activity together with enhanced myelination, associated with increased numbers of mature oligodendrocytes [36] . In the CNS, the consensus appears to emerge that the PI3K/Akt/mTOR pathway affects the differentiation of oligodendrocytes, although the precise mechanism seems to vary depending on the experimental conditions (reviewed in [37] ). However, as most of these studies have been using rapamycin as an mTOR inhibitor, and as long-term rapamycin treatment also blocks mTORC2 signalling, it remains to be determined to what extent the two branches of the mTOR cascade are responsible for the process.
As for the PNS, it remains unclear which processes the PI3K/Akt/mTOR pathway critically regulates, and how much the signalling overlaps with the MAPK pathway. It is nevertheless clear that PNS myelination is also, at least in part, controlled by mTOR signalling. Mice lacking mTOR in Schwann cells (and presumably also in oligodendrocytes) display hypomyelinated sciatic nerves [38] . Surprisingly, however, preliminary analysis of the CNS in that study did not reveal the dramatic hypomyelination observed in the PNS, although detailed examinations are still required. Moreover, the individual contributions of the two different branches of mTOR signalling have not been addressed.
Although NRG1 is the major actor in myelination in the PNS, several other factors that also signal via PI3K/Akt have been implicated in regulating myelination (Figure 2) . Analysis of brains from Igf1-knockout mice show hypomyelination and reduced myelin protein expression [39] , whereas transgenic mice overexpressing IGF-1 have hypermyelinated brains [40] . In the PNS, IGF-1 promotes myelination in dorsal root ganglia/Schwann cell co-cultures [41] . However, although Igf1-knockout mice have reduced nerve conduction velocities, they do not show reduced myelin thickness [42] , perhaps due to compensatory effects of IGF-2, or simply due to the relatively lesser importance of IGF-1 in the PNS compared with the CNS. Other potentially Aktlinked factors regulating PNS myelination/remyelination include ILK (integrin-linked kinase) [43] , extracellular matrix molecules such as laminins and their β-integrin receptors (reviewed in [44] ), as well as Rho GTPases such as Rac1 and Cdc42 (reviewed in [45] ). Taken together, the PI3K/Akt/mTOR pathway seems to integrate multiple cues from outside the Schwann cell to orchestrate myelination ( Figure 2) .
A number of factors have been implicated in Schwann cell function downstream of the NRG1/Akt/mTOR cascades ( Figure 2 ). Ca 2 + /calcineurin/NFAT (nuclear factor of activated T-cells) signalling is required for NRG1-regulated Schwann cell differentiation by transcriptionally activating Krox20/Egr2, the master transcriptional regulator of myelin proteins [46] . Krox20/Egr2 is also activated directly by phosphorylated YY1 downstream of NRG1, probably acting largely through the MAPK pathway [47] . In addition to appropriate expression of myelin proteins, accurate lipid metabolism is also required for proper myelination. Mice with Schwann cell-specific knockout of lipin1, an enzyme necessary for triacylglycerol biosynthesis, show demyelination of nerves, probably due to accumulation of phosphatidic acid [48] . Also loss of Schwann cell SCAP (SREBP-cleavageactivating protein), a protein necessary for SREBP processing, led to decreased myelination [49] . Interestingly, mTORC1 has been shown to directly phosphorylate lipin1, preventing its nuclear entry and subsequent repression of SREBP1 activity [50] .
Open issues and future perspectives
Although both oligodendrocytes and Schwann cells are myelin-producing glial cells, they are very different cell types with separate developmental origins and a different anatomy and molecular make up. Thus both shared as well as separate regulatory signalling pathways regulate Schwann cell and oligodendrocyte biology. Regarding Akt/mTOR signalling, this crucial pathway is undoubtedly important for myelination in both cell types. The currently available knowledge indicates, however, that the detailed mechanisms are likely to be different. Open questions include the following. Why does PTEN knockout, but not constitutively active Akt expression, lead to hypermyelination in the PNS? Why does constitutively active Akt expression lead to hypermyelination in the CNS, but not in the PNS? The answers may be related to technical issues due to the experimental conditions used, including transgene expression levels achieved in the different cell types for constitutively active Akt. Alternatively, the individual functions of different Akt isoforms and/or the design and artificial function of the constitutively active Akt forms employed may have differential effects on downstream signalling in oligodendrocytes compared with Schwann cells. Furthermore, alternative pathways in the PNS may act in parallel to the Akt/mTOR cascade, potentially explaining the available experimental findings.
The most important open questions include the identification of all the actors upstream and downstream of Akt/mTOR signalling that are ultimately responsible for the observed effects in myelinating glia. Also, how much cross-talk is there between Akt/mTOR signalling and other pathways? Do they work in parallel throughout the life of myelinating cells, or are specific functions regulated by Akt/mTOR only, possibly in a Schwann cell-and/or oligodendrocyte-specific manner? How many molecular overlaps and differences are involved in this signalling between the CNS and the PNS? Answering these questions will contribute not only to our understanding of axonglia interactions through development and in adulthood, but also to our understanding of common diseases affecting myelination, including neuropathies and multiple sclerosis. 
